BRCA1 and cancer: Finally, considering that RANK expression has been reported in a significant proportion of cancers arising in BRCA1 mutation carriers [105], it will also be interesting to study denosumab in the early stages of BRCA1-driven tumorigenesis and/or as add-on therapy to reduce the risk of contralateral BCa.